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Experiments were performed with BALB/c mice to elucidate the roles of humoral and cell-mediated immune
responses in the acquisition of protective immunity to Brucella ovis and to compare infection immunity with
immunity developed through vaccination with a hot saline extract (HS) of B. ovis. Mice convalescing from a
primary infection with B. ovis displayed a high level of resistance to reinfection, as evidenced by splenic
bacterial counts decreased over 10,000-fold from control groups at 2 weeks after challenge. Passive transfer
assays revealed that protection was mediated by both T lymphocytes and antibodies but that antibodies had a
substantially greater role on the basis of log units of protection that were transferred. Antibodies specific for
HS proteins in sera from convalescent mice were predominantly of the immunoglobulin G 2a and 3 isotypes.
Vaccination with HS conferred good protection against B. ovis, but protection was greatly enhanced by the
incorporation of QS-21 or other adjuvants. Protection provided by the HS vaccine resulted largely from
immune responses to its protein moieties. A critical evaluation of the protective efficacy of the rough
lipopolysaccharide component of HS was precluded by its poor immunogenicity in BALB/c mice. HS-QS-21
afforded protection against challenge infection with B. ovis as good as that which developed after a primary
infection and as good as or better than that provided by attenuated Brucella melitensis vaccine strain Rev 1.
Passive transfer experiments confirmed that the magnitudes of both humoral and cell-mediated forms of
protective immunity were equivalent in mice vaccinated with HS-QS-21 and those recovering from a primary
infection. Protective immunity to B. ovis in mice therefore resembled that to Brucella abortus, except that the
relative roles of humoral and cell-mediated immunity, rather than being equivalent, were shifted toward a
greater role for antibodies.
Brucella ovis causes a disease in sheep characterized by
epididymitis and reduced fertility in rams (12, 13, 39) and by
abortion in ewes (28, 32, 35). Ovine brucellosis is recognized as
the cause of major economic losses in countries in which sheep
husbandry is an important industry (14). Vaccination is the
only method of control suitable for countries with a high
incidence of this disease (6), and at present, live attenuated
Brucella melitensis Rev 1 is still the strain most widely used for
this purpose (9, 21, 25, 33). However, Rev 1 produces serolog-
ical responses that interfere with the diagnosis of both B. ovis
and B. melitensis infections (9, 26, 42) and is pathogenic for
humans (7). Moreover, its use is now prohibited in countries
free of B. melitensis. Numerous attempts to develop killed
vaccines that are as effective as Rev 1 have met with limited
success (1, 11, 15, 34, 50).
B. ovis is a natural rough species and so lacks the 0
polysaccharide that constitutes the principal surface antigen of
smooth Brucella species (17). A hot saline extract (HS) ob-
tained from B. ovis REO 198 contained rough lipopolysaccha-
ride (R-LPS) and several proteins, including abundant group 3
outer membrane proteins (16, 24, 41). Rams infected with B.
ovis produced antibody responses to the R-LPS and proteins in
the HS (24, 40, 41). Therefore, we believed that one or more
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HS antigens, particularly the surface-exposed group 3 protein,
might induce a protective immune response to B. ovis. In fact,
we have preliminary evidence that HS incorporated with an
adjuvant induced significant levels of protection in rams
against B. ovis (8).
Despite the recognized economic importance of ovine bru-
cellosis and ongoing efforts to develop alternative vaccines to
Rev 1, nothing is known about the nature of protective
immunity to this disease. This stands in marked contrast to
Brucella abortus, for which the mouse model has been exten-
sively employed in recent years to study a variety of host-
parasite interactions and the development of protective immu-
nity (5). The objectives of the present work were, first, to use
the mouse model in order to define the roles of humoral and
cell-mediated immune responses in the elimination of B. ovis
in a primary infection. We then wished to evaluate the
protective qualities of the HS vaccine and to compare the
magnitude of protective immunity acquired through vaccina-
tion with that which developed during a primary infection. Our
selection of a vaccine for a future field trial with rams would
depend upon its ability to induce protection in both humoral
and cell-mediated compartments at least as good as that which
followed recovery from disease.
MATERIALS AND METHODS
Mice. Female BALB/cByJ mice were purchased from the
Jackson Laboratory (Bar Harbor, Maine) 1 week before use.
Mice to be used in vaccination experiments were shipped at 5
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weeks of age, while animals scheduled for passive transfer
experiments were shipped at 9 weeks of age.
Bacterial strains. B. ovis PA was obtained from J. M. Verger
(Station de Pathologie Infectieuse et Immunit6, Institut Na-
tional de la Recherche Agronomique, Nouzilly, France). B.
melitensis 16M and Rev I were supplied by G. G. Schurig
(Virginia-Maryland Regional College of Veterinary Medicine,
Blacksburg, Va.). B. ovis PA and B. melitensis 16M were used
as challenge strains after two serial passages in BALB/c mice
and isolation in pure culture from spleens. Stock cultures were
prepared from 48-h growth on Schaedler blood agar plates and
were stored at - 70°C in Albimi broth (Difco Laboratories,
Detroit, Mich.). For infection, contents of freshly thawed vials
were diluted with sterile phosphate-buffered saline (PBS) to
the desired concentration. Exact numbers of cells were estab-
lished retrospectively by viable counts (36).
Antigens for vaccines and immunoassays. HS from B. ovis
REO 198 was obtained as described previously (17, 41) by
suspending live cells in physiological saline (10 g of packed
cells per 100 ml) and heating the suspensions in flowing steam
for 15 min. After centrifugation at 12,000 x g for 15 min, the
supernatant was dialyzed for 2 days at 4°C against several
changes of distilled deionized water. The dialyzed material was
centrifuged for 5 h at 100,000 x g, and the pellet (HS) was
suspended in distilled deionized water and lyophilized. The
product produced a typical profile by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, with group 3 outer mem-
brane proteins by far the dominant component (data not
shown). HS proteins (HS-PCP) were purified by extraction of
2 mg of HS with 7 ml of a mixture of petroleum ether,
chloroform, and phenol (PCP) (23) for 1 min at 16,000 rpm in
a homogenizer (Sorvall Omnimixer; Dupont Co., Wilmington,
Del.). After centrifugation at 12,000 x g, the sediment (HS-
PCP) was washed once and then suspended in distilled deion-
ized water and lyophilized (41).
R-LPS was obtained from HS by elimination of proteins with
the PCP protocol followed by precipitation of R-LPS from the
phenol phase with water (41). The final product had a protein
content of 0.6% (dry weight) and a 2-keto-3-deoxyoctulosonic
acid content of 2.8% (dry weight), which represented an LPS
content of approximately 51% (37).
Adjuvants. QS-21, a purified derivative of saponin (31), was
a gift from Cambridge Biotech Corp. (Worcester, Mass.). The
pluronic polyol L-121 was supplied by the BASF Wyandette
Co. (Parsippany, N.J.), and the purified oleic ester Montanide
888 was a gift from Seppic, Inc. (Paris, France). N-Acetylmu-
ramyl-L-threonyl-D-isoglutamine (tMDP) was a gift from Syn-
tex, Inc. (Palo Alto, Calif.). Squalane was purchased from
Sigma Chemical Co. (St. Louis, Mo.).
Preparation and administration of vaccines. Subcellular
vaccines were solubilized in PBS and injected subcutaneously
(s.c.) over the back or into the hind footpads, with or without
adjuvant, in a final volume of 0.1 ml. QS-21 in aqueous solution
was mixed with the antigen to a concentration of 150 ,ug/ml (15
p.g per dose). An emulsion of L-121, squalane, and antigen in
PBS with 0.2% Tween 80 (PBS-Tween) was prepared as
described previously (53). A dose of vaccine contained 20 ,ug of
antigen, 2.5 ,ug of L-121, 5 [l of squalane, and 95 ,ul of
PBS-Tween. Stable emulsions of antigen with Montanide 888
were produced by vortexing the adjuvant with squalane and
antigen solution for 7 min. A dose of vaccine contained 20 pLg
of antigen, S [l of Montanide 888, 45 p.l of squalane, and 50 [I1
of PBS. tMDP was incorporated into some of the vaccines to a
concentration of 50 p.g per mouse.
B. melitensis Rev 1 was inoculated s.c. in a volume of 0.1 ml
containing 5 x 104 CFU.
Blood sampling. Mice were bled under light anesthesia from
the retroorbital sinus or the heart. Serum samples were stored
at - 70°C unless used for passive transfer assays immediately
upon separation.
Quantitation of bacterial numbers in the spleen. Mice were
killed by CO2 asphyxiation. Spleens were homogenized, di-
luted serially, and plated (36). Colonies were counted after
incubation for 3 days (B. melitensis) or 4 to 5 days (B. otis) at
37°C under 10% CO,. In groups vaccinated with Rcv I,
numbers of Rev I cells were determined by doing counts on
parallel sets of plates that were either incubated without CO,
(to exclude B. oivis) or contained 2.5 p.g of streptomycin per ml
(to exclude B. melitensis 16M) (2).
T-lymphocyte enrichment. B cells were depleted by a single
negative panning step by using the technique described by
Araya et al. (3) without modification. Percentages of B cells
(surface immunoglobulin [Ig] positive) and of CD4+, CD8+,
and Mac-1+ cells were determined by immunofluorescence
assays (3).
Experimental design. (i) Time course of infection. Mice (6
weeks old) were inoculated intravenously (i.v.) with 5 x 103
CFU of B. ovis PA or 5 x I04 CFU of B. nmelitenisis 16M in 0.1
ml of PBS. At selected times postinoculation (p.i.), groups of
mice (ni = 5 unless noted otherwise) were killed, and spleens
were processed for quantitative counts.
(ii) Vaccination and challenge trials. Mice (6 weeks old) in
groups of five were vaccinated either once with live Rev 1 or
twice at an interval of 4 weeks with subcellular vaccines. Five
weeks after the first vaccination, mice were challenged by i.v.
inoculation of B. ovis PA or B. melitenisis 16M. Two weeks after
challenge, mice were killed and spleen counts were performed.
In most experiments, blood samples were taken prior to
vaccination, immediately before challenge, and at the time of
sacrifice.
(iii) Passive transfer assays. Donor mice at 10 weeks of age
were either vaccinated twice with HS-QS-21 or inoculated i.v.
with 5 x 103 CFU of B. ovis PA. Five weeks after the first
vaccination and at selected times after infection, donor groups
were exsanguinated and T-lymphocyte suspensions were pre-
pared from their spleens or popliteal lymph nodes. Groups of
five recipients (10 weeks old) were injected i.v. with pooled
suspensions of lymphocytes (3 x 107 viable cells in 0.4 ml of
Dulbecco's modified Eagle's medium) or pooled antisera (0.1
ml) from a donor group (3). After I h, recipients were
challenged i.v. with 5 x 103 CFU of B. ovis PA, and 2 weeks
thereafter, mice were killed and spleen counts were made.
Control groups received PBS since it had been established that
there were no differences in splenic numbers of B. ovis between
groups that were injected with 0.1 ml of PBS and those that
received either 0.1 ml of normal mouse serum or 3 x 1()
normal T cells prior to inoculation with B. ovis (difference in
mean counts, <0.1 log," unit). Recipient groups receiving T
cells were bled prior to sacrifice.
KELA. Antibodies against HS and R-LPS were measured in
an indirect, computer-assisted kinetics-based enzyme-linked
assay (KELA), as described previously (53), with a goat
anti-mouse IgM, IgG, and IgA horseradish peroxidase conju-
gate (Cappel, Organon Teknika, Durham, N.C.). In selected
tests, goat anti-mouse horseradish peroxidase conjugates spe-
cific for individual isotypes (IgM, IgGl, IgG2a, IgG2b, and
IgG3) (Southern Biotechnology Associates, Birmingham, Ala.)
were used under the same conditions. The rate of the reaction
between substrate solution and enzyme, expressed as slope, is
directly proportional to the amount of antibody in the sample
(51) and was determined from linear regression analysis of
time versus absorbance. Data from assays performed on sep-
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FIG. 1. (a) Growth curve of twice-passaged B. ovis PA in spleens of
BALB/c mice following i.v. inoculation of approximately 5 x 103 CFU.
Solid and open circles represent separate experiments for which n at
each time point was 5 and 3. The first interval tested was at 1 h p.i.
Growth was not detected in any of the spleens at 12 weeks p.i., so a
loglo value of 2.12 was assigned to the group according to the previous
convention (36). (b) Growth curve of twice-passaged B. melitensis 16M
in spleens of BALB/c mice following i.v. inoculation of approximately
5 x 104 CFU. The first interval tested was at 1 h p.i. (n = 5). Bars,
standard deviations.
arate plates and on different days were normalized by regres-
sion analysis from a standard curve obtained by inclusion of the
same set of standards on each plate. On the basis of the linear
relationship between the log of slope values and antibody titers
(53), slope values (x 1,000) of >150 corresponded to high
antibody titers, 50 to 150 slope units corresponded to moderate
titers, and 15 to 50 units corresponded to low titers. Prior to
infection or vaccination, slope values (x 1,000) for HS and
R-LPS averaged 10 and 12, respectively.
Statistical methods. A mean value for each spleen count was
obtained by averaging the triplicate values following log con-
version (36). Log units of protection were calculated by
subtracting individual counts of the principal group from the
mean count of the corresponding control group (3). Statistical
analyses were performed with Student's t test (48).
RESULTS
Growth patterns of B. ovis PA and B. melitensis 16M. After
two passages in mice, B. ovis PA grew readily in the spleen.
Low inoculum numbers became established and increased by
approximately 5 logs during the first 2 1/2 weeks p.i., followed
by a gradual decline (Fig. la). The plateau at 2 weeks p.i. (Fig.
la) was not reproduced in subsequent experiments in which
counts at 2 weeks p.i. were at least 1 log higher (Table 1 and
see Tables 4 to 6). The challenge dose selected for most
experiments was 5 x 103 CFU, with an interval of 2 weeks
between challenge and sacrifice. In some experiments, a 10-
fold-higher challenge dose was used, resulting in splenic cell
numbers exceeding 108 by 2 weeks p.i. (see Tables 3 and 5).
Twice-passaged B. melitensis 16M produced a growth curve
over the first 3 weeks p.i. resembling that of virulent B. abortus
2308 (36). Numbers increased during the first 1 1/2 weeks p.i.,
peaked at levels much lower than those of B. ovis PA, and then
plateaued (Fig. lb). A challenge dose of 5 x 104 CFU of strain
16M was used with a challenge-to-sacrifice interval of 2 weeks.
Rev 1 replicated actively in the spleens of BALB/c mice
during the first 2 weeks p.i. (data not shown), in accord with
prior observations (10).
None of these strains produced clinical signs of disease.
Infection immunity. Mice convalescent from infection with
B. ovis PA were highly resistant to reinfection with the
homologous strain. In separate experiments, groups of mice
challenged with B. ovis PA (5 x 103 CFU) 10 1/2 or 13 weeks
after an initial infection exhibited 4.57 and 5.39 log units of
protection (P < 0.001), respectively, compared with control
groups of naive mice.
Immunity through vaccination with HS. Mice were vacci-
nated with graded quantities of HS, with and without QS-21.
High levels of protection were obtained with 20 or 2 ,ug of HS
incorporated with QS-21, whereas only the higher dose of
antigen was protective in the absence of adjuvant (Table 1). A
vaccine composed of 20 p.g of HS plus QS-21 was selected for
subsequent studies. A clear association existed among the
groups between the concentration of circulating HS-specific
antibodies at the time of challenge and the level of protection
obtained (Table 1). The presence of QS-21 resulted in large
and highly significant (P < 0.01 to P < 0.001) increases in
antibodies of the IgGl, IgG2a, and IgG2b isotypes (Table 2). A
similar distribution of isotypes occurred in three other serum
pools of mice that had been vaccinated with HS-QS-21, except
that the level of IgG3 antibodies was substantially higher
(Table 2). Whereas IgG2a and IgG2b antibodies predomi-
nated in mice vaccinated with HS-QS-21, infection with B. ovis
induced predominantly IgG2a and IgG3 antibodies, with IgGl
at the lowest level (Table 2).
In another experiment with a 10-fold-higher challenge dose,
inclusion of QS-21 with HS resulted in significantly higher
antibody levels (P < 0.001) and significantly better protection
than that provided by HS alone (P < 0.01) or Rev 1 (P < 0.01)
(Table 3). Incorporation of adjuvant L-121 or Montanide 888,
with or without tMDP, also induced high concentrations of
TABLE 1. Protection against B. ovis provided by vaccination with graded quantities of HS with and without QS-21 adjuvant
Treatment
)a HS (p.g) QS-21b KELA slope (103) at Log,() units of B. ovis Log units of
group (n = 5)a (>g ~ challenge (x ± SD)' in spleen (x ± SD) protectiond
1 20 + 406 ± 21 3.10 ± 0.01 4.11***
2 20 - 201 ± 50 4.52 ± 1.38 2.69**
3 2 + 282 ± 24 3.50 ± 0.65 3.71***
4 2 - 79 ± 23 6.97 ± 1.15 0.24t
5 0.2 + 60 ± 30 7.39 ± 0.20 -0.18t
6 0.2 - 25 ± 19 6.67 ± 1.34 0.54t
7 None (PBS) - 4 ± 1 7.21 ± 0.46
aMice were vaccinated twice over a 4-week interval and challenged i.v. with 5 x 103 CFU of B. ovis PA 1 week after the second vaccination. Spleens were cultured
2 weeks later.
b +, with QS-21; -, without QS-21.
' KELA analyses were performed with HS antigen.
d ***p C 0.001 and **P . 0.01 compared with PBS control group; t, not significant.
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TABLE 2. Isotype distribution of antibodies specific for HS antigens in sera of mice vaccinated with HS or infected with B. ovis
Antibody isotype (slope [103])"
Treatment
IgM IgG3 IgG2b IgGI IgG2a
Vaccination
HS (20 p.g)-QS-21" 133 ± 104t 118 ± 54t 299 ± 73* 196 ± 53** 307 ± 44***
HS in PBS' 70 ± 35 101 ± 80 142 77 91 ± 45 97 ± 54
HS (20 p.g)-QS-2ld 188 ± 48 240 ± 55 327 ± 75 179 ± 65 289 ± 60
B. ovis infection (5 x 103 CFU)' 51 ± 13 173 ± 34 111 ± 17 39 ± 17 221 ± 9
" KELA assays with HS antigen. Values are means ± standard deviations. t, not significant. **P < 0.01 and ***P < t).001 compared with the group receiving HS
in PBS.
b- Treatment groups 1 and 2, respectively, from Table 1. The mice in each group were bled 1 week after the second vaccination.
"Three serum pools used in passive transfer assays. Mice were bled 1 week after the second vaccination. Pools were composed of serum samples from 10 to 20 donor
mice.
e Three serum pools used in passive transfer assays. Mice were bled at 9, 10, and 13 weeks p.i., respectively. Each pool was composed of serum samples from 10 donor
mice.
antibodies and high levels of protection (Table 3) that did not
differ significantly from the values recorded for QS-21.
Both HS-QS-21 and live Rev 1 vaccines produced significant
protection against B. ovis (P < 0.001 and P < 0.01, respec-
tively) (Table 4), but protection provided by HS-QS-21 was
significantly greater (P < 0.01). In contrast, the HS-QS-21
vaccine failed to provide any protection against B. melitensis
16M, while Rev 1 was highly protective (Table 4). A repetition
of this experiment produced the same results, except that
HS-QS-21 and Rev 1 gave equivalent protection against B. ovis
(data not shown). In two further comparisons, protection
against B. ovis PA provided by vaccination with HS-QS-21 was
equivalent to, or significantly greater than, that which resulted
from vaccination with Rev-1 (data not shown).
Vaccination with HS-PCP, the purified protein fraction of
HS, provided protection against B. ovis as good as that with HS
when a high challenge dose (5.8 x 104 CFU) was used,
whereas purified R-LPS was completely ineffective (Table 5).
The same results were obtained with HS and HS-PCP in two
repetitions of this experiment with a 10-fold-lower challenge
dose. With the lower challenge dose, R-LPS was also protec-
tive, although at levels 10-fold or more below those of HS-PCP
(data not shown). Mice vaccinated with R-LPS produced
extremely low antibody responses to that antigen, and in mice
vaccinated with intact HS, the R-LPS-specific antibodies rep-
resented a negligibly small proportion of the total antibody
response (Table 5 [other data not shown]). The immunogenic-
ity of R-LPS could not be improved by coupling it to bovine
serum albumin (BSA) (data not shown).
Passive transfer of immunity. T cells from spleens of
convalescent donors (Table 6, group 1) provided significant
protection against the homologous challenge strain (0.80 log
unit, P < 0.01), and serum antibody levels in recipient group 1
were no different from those of the control group 7, thus
ensuring that protection was not the result of antibodies
produced by residual B cells in the transferred population. This
result was repeated in a separate experiment with two other
T-cell preparations (log units of protection, 1.17 [P < 0.001]
and 0.92 [P < 0.01]). No protection was obtained in mice
receiving splenic T cells from donors vaccinated s.c. over the
back with HS-QS-21 (Table 6, group 3), although in a repeti-
tion of this experiment, some protection was demonstrated
(0.58 log unit, P < 0.05). In contrast, popliteal lymph node T
cells from mice vaccinated in the hind footpads provided
excellent protection (1.32 log units, P < 0.001)(Table 6, group
5), and the low number of residual B cells that were transferred
(0.9%) precluded a significant contribution from antibodies.
Antiserum pools from all three donor groups provided signif-
icant levels of protection (P < 0.001 to P < 0.05) that were much
higher in log units than protection given by the corresponding
pools of T cells (Table 6). In another experiment with the same
antiserum pools, results were very similar (data not shown),
except that protection with the group 4 serum (HS, s.c. vacci-
nation) was higher and more consistent (3.31 log units, P <
0.01). In a separate experiment, antisera from convalescent or
vaccinated mice again provided high levels of protection (rang-
ing from 2.36 [P < 0.01] to 4.31 [P < 0.001] log units) that
exceeded the protection obtained from the corresponding pools
of T cells by 1.39 to 3.39 log units (data not shown).
TABLE 3. Protection against B. ovis provided by vaccination with HS in selected adjuvants
Treatment KELA slope (103) at Logl0 units of B. ot'is Log units of
group (n = 5)" g juvan challenge (x ± SD)" in spleen (x ± SD) protection'
I HS (20 p.g) QS-21 425 ± 26 4.00 ± 1.07 4.10***
2 HS (20 jig) L-121 384 ± 28 5.28 ± 1.40 2.82**
3 HS (20 [Lg) L-121-tMDP 392 ± 38 4.14 ± 2.71 3.96*
4 HS (20 ,ug) Montanide 888 309 ± 35 3.63 ± 1.92 4.47**
5 HS (20 ,ug) Montanide 888-tMDP 328 ± 64 2.87 ± 1.93 5.23**
6 HS (20 ,ug) None 186 ± 56 6.42 ± 0.88 1.68**
7 Rev I (live) None 13 ± 6 7.08 ± 0.31 1.02**
8 None (PBS) None 10 ± 2 8.10 ± 0.15
"Groups 1 to 6 were vaccinated s.c. twice over a 4-week interval. Group 7 was inoculated s.c. on day 0 with 5 x 10' CFU of Rev 1. All mice were challenged i.v.
with 5 x 104 CFU of B. ovis PA 5 weeks after the first treatment, and spleens were cultured 2 weeks after challenge.
b KELA analyses were performed with HS antigen.
' ***P - 0.001, **P - 0.01, and *P - 0.05 compared with the PBS control group.
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TABLE 4. Comparison of vaccinations with HS and Rev 1 against challenge with B. ovis and B. melitensis
Treatment Log,(l units of Log units of
group (n = 5)' ~ Vaccine Challenge brucellae in spleen protectionb(x ±SD)
1 HS (20 K.g)-QS-21 B. ovis PA 2.65 ± 1.14 4.69***
2 Rev 1 (live) B. ovis PA 5.57 ± 0.82' 1.77**
3 None (PBS) B. ovis PA 7.34 ± 0.12
4 HS (20 ,ug)-QS-21 B. melitensis 16M 6.64 ± 0.30 0.04t
5 Rev 1 (live) B. melitensis 16M 3.78 ± 0.73c 2.90***
6 None (PBS) B. melitensis 16M 6.68 ± 0.10
Groups I and 4 were vaccinated twice over a 4-week interval. Groups 2 and 5 were vaccinated s.c. on day 0 with 5 x 104 CFU of Rev 1. Challenge inoculations
of 5 x 103 CFU of B. ovis PA and 5 x 104 CFU of B. melitensis 16M were made i.v. Spleens were cultured 2 weeks after challenge.
***P ' 0.001 and **P c 0.01 compared with PBS control groups. t, not significant.
No Rev I colonies were detected in the spleens.
DISCUSSION
The data presented here demonstrate that the BALB/c
mouse, recognized as a useful model for brucellosis caused by
B. abortus (5), may also be used to advantage for studying B.
ovis. Thus, B. ovis replicated readily in the spleen (Fig. la) and
liver (29a) to produce a chronic and asymptomatic infection
which was overcome through a potent immune response
(Table 6). In a recent study with B. ovis PA in outbred CD1
mice, bacterial replication was limited or failed to occur (29).
This was probably due in part to greater inherent resistance of
the CD1 strain, which was also more resistant than BALB/c
mice to B. abortus (52). In addition, it is likely that the
twice-passaged strain used in this study was more virulent.
Although the status of B. ovis as a facultative intracellular
bacterium capable of survival in macrophages has yet to be
established, passive transfer experiments now demonstrate
that, in mice, protection is partially attributable to cell-medi-
ated immunity (Table 6). The identity of the protective cell
type or types is not yet known. The induction by B. ovis of a
dominant CD4+, THi population known to be protective
against several protozoan agents (45) was suggested by the
predominance in infected mice of IgG2a and IgG3 antibodies,
coupled with minimal IgGl responses (Table 3). B. abortus,
which stimulates a polyclonal THI response (22, 49), induces
primarily IgG2a and IgG3 antibodies specific for covalently
bound haptens (46) or B. abortus outer membrane proteins
(19). Recent evidence (47) indicates that gamma interferon
exerts control over IgG3 as well as IgG2a synthesis. Since there
is now strong support for a protective function of natural killer
cells (18) and -y5 T cells (27, 43) in murine listeriosis, the
involvement of one or both of these cell types in protection
against B. ovis is also possible. However, excellent protection
was transferred by lymph node lymphocytes in which CD4+
and CD8+ cells accounted for the total cell population (Table
6), indicating that these cell populations had an important role
in providing cell-mediated immunity to B. ovis.
Whereas immune T cells were largely absent from the
spleens of HS-vaccinated mice prior to challenge infection, T
cells from the popliteal nodes of mice vaccinated in the hind
footpads provided the highest level of protection of any T-cell
preparation tested (Table 6 and other data). We believe that
the paucity of immune T cells in the spleens of HS-vaccinated
mice prior to challenge infection occurred because, during the
first weeks after the two vaccinations, these cells would have
localized predominantly in the inflamed draining lymph nodes,
which would have contained substantial quantities of antigen
absorbed from the injection sites. In like fashion, immune T
cells would have localized in the spleens of mice undergoing
active infection in that organ, including the spleens of the
HS-vaccinated mice following i.v. challenge infection.
The remarkably high levels of protection obtained with
antibodies in passive transfer assays (Table 6), orders of
magnitude higher than those achieved against B. abortus (3, 4,
20), may have several explanations. In B. abortus infection, for
example, passive protection by IgG antibodies against attenu-
ated vaccine strain 19, which is readily killed within macro-
phages when opsonized by IgG antibodies, is consistently 1 log
unit greater than that against virulent strain 2308, which is
more resistant to killing when comparably opsonized (20, 30).
The protective functions of antibodies against B. ovis could
have included opsonization with enhancement of intracellular
killing or mediation of extracellular killing by complement or
through antibody-dependent cellular cytotoxicity by natural
killer or other effector cells.
Protection transferred by three antiserum pools from con-
valescent mice ranged from 2.36 to 5.25 log units, while that
from HS-vaccinated donors ranged from 2.68 to 5.10 log units.
It is unclear why some antiserum pools conferred higher levels
TABLE 5. Protection against B. ovis provided by vaccination with HS or its protein and LPS fractions
KELA slope (103) at challenge
Treatment Vaccineb (x ± SD) Log1o units of B. ovis Log units of
group (n = 5)" in spleen (x ± SD) protection'
HS R-LPS
1 HS 451 ± 11 43 ± 19 5.66 ± 1.27 2.54**
2 HS-PCP 259 ± 15 20 ± 4 5.63 ± 1.44 2.57**
3 R-LPS 38 ± 20 18 ± 12 8.21 ± 0.07 -0.01t
4 None (PBS) 19 ± 5 ND 8.20 ± 0.15
"Mice were vaccinated twice over a 4-week interval and were challenged i.v. with 5.8 x 104 B. ovis PA cells 1 week after the second vaccination. Spleens were cultured
2 weeks later.
b All vaccines contained 20 ,ug of antigen combined with QS-21. The control group received PBS in place of vaccine.
' **P c 0.01 compared with the PBS control group. t, not significant.
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TABLE 6. Passive transfer of protection against B. ovis by immune T cells and antiserum
Recipient KELA slope (103) of Log1,( units of B. ovis Log units of
group (n =5)T terminal bleeds (x ± SD)' in spleen (x ± SD) protection"
1 B. ovis, 10 wk, T cells 37 ± 16 6.57 ± 0.26 0.80**
2 B. ovis, 10 wk, serum ND 2.12 ± 0' 5.25***
3 HS, s.c. vaccination, T cells 74 ± 16 7.40 ± 0.22 -0.03t
4 HS, s.c. vaccination, serum ND 4.69 ± 1.69 2.68*
5 HS, footpad vaccination, T cells NA 6.05 ± 0.17 1.32***
6 HS, footpad vaccination, serum ND 2.27 ± 0.36 5.10***
7 None (PBS) 33 ± 12 7.37 ± 0.42
"Recipients received T cells (3 x 107) or antiserum (0.1 ml) i.v. 1 to 2 h before i.v. challenge with 5 x 103 CFU of B. ovis PA. Spleens were cultured 2 weeks later.
b Donor groups were as follows: B. ovis, 10 wk, group inoculated i.v. with 5 x 103 CFU of B. ovis PA 10 weeks previously; HS, s.c. vaccination, group vaccinated s.c.
over the back twice over a 4-week interval with HS (20 ,ug)-QS-21 and sacrificed 1 week after the second vaccination; HS, footpad vaccination, group vaccinated in
each hind footpad twice over a 4-week interval with HS (20 p.g)-QS-21 and sacrificed 1 week later. Spleen cells were harvested from B. ovis, 10 wk, and HS, s.c.
vaccination, donors, and popliteal lymph nodes were harvested from HS, footpad vaccination, donors. The compositions of the transferred cell populations were as
follows: B. ovis, 10 wk, CD4+, 64%; CD8+, 24%; secretory Ig+, 2.5%; Mac-1+, 9.0%; HS, s.c. vaccination, CD4+, 63%; CD8+, 22%; secretory Ig+, 2.0%; Mac-1+, 25%;
HS, footpad vaccination, CD4+, 84%; CD8+, 16%; secretory Ig+, 0.9%; Mac-1+, 0%. KELA slopes (103) of the donor serum pools tested against HS antigen: B. ovis,
10 wk, 266; HS, s.c. vaccination, 455; HS, footpad vaccination, 415.
' KELA analyses were performed with HS antigen. ND, not done. NA, not available because of technical error.
d ***P < 0.01, ***P < 0.001, and *P < 0.05 compared with PBS control group. t, not significant.
e B. ovis was not detected in any of the spleens, so a logl0 value of 2.12 was assigned to the group according to the previous convention (36).
of protection than others. Such differences were not associated
with total antibody concentrations determined by KELA (Ta-
ble 6). In fact, antiserum pools from convalescent mice were
overall as protective as those from vaccinated groups, despite
lower levels of antibodies of all isotypes (Tables 2 and 6). Even
though there was no difference in the recognition of antigens
on methanol-killed whole B. ovis cells by convalescent phase
sera and sera induced by the heat-treated HS antigens as
judged by KELA (28a), some differences in the fine specificity
of antibodies that could have affected protection may have
existed between them.
The importance of the protein constituents of HS in ac-
counting for protective immunity was illustrated by the induc-
tion of equivalent protection by purified proteins (HS-PCP)
and intact HS (Table 5). Purified R-LPS also induced low
levels of protection against a lower challenge dose, but the
poor immunogenicity of R-LPS in BALB/c mice (Table 5)
precludes an unqualified judgment of its protective efficacy.
Although outer membrane protein antigens of B. ovis and B.
melitensis are antigenically related (24, 41, 44), HS-specific
antibodies would probably not have been protective against B.
melitensis with its surface-exposed 0 polysaccharide, and cross-
protective cell-mediated immune responses were apparently
not induced by HS (Table 4).
The combination of HS and QS-21 fulfills our criteria for
selection of an appropriate vaccine for a field trial with rams.
Aside from its potency in inducing antibodies (Tables 1 to 3
and 5) that were demonstrated to be protective (Table 6),
HS-QS-21 evoked a protective cell-mediated immune re-
sponse as good as that obtained from the T cells of convales-
cent mice (Table 6). It remains to be seen whether the
protective T cells induced by vaccination with HS-QS-21 and
through primary infection with B. ovis are distributed into the
same subsets. However, the ability of QS-21 to stimulate the
formation of a major histocompatibility complex class I-re-
stricted CD8 T-cell response to a simple protein antigen has
already been established (38) and represents an essential
attribute of an adjuvant for subcellular vaccines against intra-
cellular parasites. An additional important advantage of QS-21
lies in the extreme simplicity of vaccine preparation and
administration, coupled with the absence of oils and emulsify-
ing agents from the injected product.
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